July 18, 2017
August 18, 2021
Study CC-90010-ST-001 is an open-label, Phase 1a, dose escalation and expansion, First-in-human (FIH) clinical study of CC-90010 in subjects with advanced or unresectable solid tumors and relapsed and/or refractory advanced Non-Hodgkin's lymphoma (NHL). The dose escalation part (Part A) of the study will explore escalating oral doses of CC-90010 to estimate the maximum tolerated dose (MTD) of CC-90010. The expansion part (Part B) will further evaluate the safety and efficacy of CC-90010 administered at or below the MTD in the following cohorts: Cohort 1: relapsed and/or refractory DLBCL approximately 20-25 evaluable subjects at 45 mg CC-90010 4-days-on/24-days-off in each 28-day cycle Cohort 2: advanced BCC -enrollment stopped due to recruitment challenges Cohort 3: relapsed and/or refractory DLBCL -approximately 15 evaluable subjects at 30mg CC-90010 3-dayson/11-days-offin each 28-day cycle. The enrollment of subjects with R/R DLBCL in Cohort 1 and Cohort 3 was closed due to Company's strategic decision and not due to any safety concern or lack of preliminary antitumor efficacy. The food effect assessment (Part C, Spain only) will evaluate the impact of food on CC-90010 when administered at the RP2D of 45 mg 4-days-on/24-days-off (180 mg per 28-day cycle), by comparison of the PK parameters following fasted and fed (high-fat, high-calorie meal) conditions.
Parts A, B and C will consist of 3 periods: Screening, Treatment and Follow-up. Screening Period: The Screening Period starts 28 days (± 3 days) prior to first dose of CC-90010. The informed document (ICD) must be signed and dated by the subject and the administering staff prior to the start of any other study procedures. All screening tests and procedures must be completed within the 28 days (±3 days) prior to the first dose of CC-90010. Treatment Period: During the Treatment Period, CC-90010 was initially administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28-day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data by the SRC. Following completion of dose escalation in Part A, selected expansion cohorts will receive CC-90010 in Part B. The SRC determined the RP2D for Part B to be 45 mg CC-90010 given once daily for 4 consecutive days on followed by 24 consecutive days off (4-days-on/24-days-off) in each 28-day cycle. There are 3 cohorts in Part B expansion. A cohort of up to approximately 20-25 subjects with relapsed and/or refractory DLBCL (Cohort 1) enrolled at the RP2D.. Enrollment in advanced BCC (Cohort 2) will be stopped due to recruitment challenges. An additional cohort of approximately 15 evaluable subjects with R/R DLBCL (Cohort 3) will be enrolled under an alternative dosing regimen of 30 mg CC-90010 3days-on/11-days off in each 28-day cycle. The enrollment of subjects with R/R DLBCL in Cohort 1 and Cohort 3 was closed due to Company's strategic decision and not due to any safety concern or lack of preliminary antitumor efficacy. The food effect assessment (Part C, Spain only) will evaluate the impact of food on CC-90010 when administered at the RP2D of 45 mg 4-days-on/24-days-off, by comparison of PK parameters following fasted and fed (high-fat, high-calorie meal) conditions in approximately 24 subjects with advanced solid tumors. Follow-up Period: In the Follow-up Period, subjects will be followed for 28 days (± 3 days) after the last dose of CC-90010 for safety. After the Safety Follow-up visit, all subjects will be followed every subsequent 3 months (± 2 weeks) for survival follow-up for up until 2 years or until death, lost to follow-up, or the End of Trial, whichever occurs first.
|Experimental: CC-90010 in patients with solid tumors and NHL
Subjects will be administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data.
CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
1. Age = or > 18 years.
2. For subjects enrolling in food-effect assessment (Part C) only: a. Subject must agree
and be willing to consume a standard high-fat, high-calorie meal. b. Subject must be
willing to refrain from caffeine or xanthene-containing products (coffee, tea, cola,
chocolate, etc.) for 48 hours prior to dosing on Cycle 1 Day 4 and Cycle 2 Day 4 and
up to 24 hours post dose.
3. Subjects with histological or cytological confirmation of either:
1. In Part A, advanced or unresectable solid tumors or advanced relapsed and/or
refractory Non-Hodgkin lymphoma (ie, Diffuse large B-cell lymphoma and Follicular
lymphoma or Marginal zone lymphoma) including those who have progressed on (or
not been able to tolerate due to medical comorbidities or unacceptable toxicity)
standard anticancer therapy or for whom no other approved conventional therapy
2. In Part B dose expansion, - Cohorts 1 and 3: relapsed and/or refractory DLBCL
following at least 2 prior lines of therapy (e.g. have failed at least one line
of standard therapy and have received at least one prior line of salvage therapy)
OR have failed at least one prior line of standard therapy and are not eligible
for autologous stem cell transplant (ASCT) or have declined ASCT; transformed
lymphoma following chemotherapy for lower grade lymphoma and at least two
standard treatment regimen for DLBCL.
Subjects with two or more lines of systemic therapy must have been treated with
and have lack of response after chimeric antigen receptor (CAR) T-cell therapy,
if such therapy is available, OR be ineligible for CAR T-cell therapy at the time
of enrollment, OR subject declined CAR T-cell therapy.
- Cohort 2: advanced basal cell carcinoma including those who have progressed on
(or not been able to tolerate due to medicalcomorbidities or unacceptable
toxicity) standard anticancer therapy or for whom no other approved conventional
In Part C, advanced or unresectable solid tumors including those who have
progressed on (or not been able to tolerate due to medical comorbidities or
unacceptable toxicity) standard anticancer therapy or for whom no other approved
conventional therapy exist
4. At least one site of measurable disease for subjects with solid tumors;
bi-dimensionally measurable disease on cross sectional imaging with at least one
lesion >1.5 cm for subjects with NHL. For subjects with rare malignancies evaluable
disease can be considered.
5. Tumor biopsies whenever safe and feasible will be collected in Part A, except for
subjects with GBM. Subject consents to mandatory tumor biopsies (Screening and on
treatment) in Part B. In exceptional circumstances an exemption waiver may be granted
by the Sponsor for this criterion
6. ECOG PS of 0 to 1.
7. Females of childbearing potential (FCBP)1 must:
• Either commit to true abstinence from heterosexual contact (which must be reviewed
on a monthly basis and source documented) or agree to use, and be able to comply with,
at least two effective contraceptive methods (oral, injectable, or implantable
hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive
with spermicide; or vasectomized partner), one of which must be barrier, from signing
the ICD, throughout the study (including dose interruptions), and for up to 6 months
and 16 days following the last dose of CC-90010; and
- Avoid conceiving for 6 months and 16 days after the last dose of CC-0010.
- Agree to not donate oocytes while receiving CC-90010 and for 6 months and 16 days
after the last dose of CC-90010.
8. Males must practice true abstinence2 (which must be reviewed on a monthly basis) or
agree to use a condom (a latex condom is recommended) during sexual contact with a
pregnant female or a FCBP and will avoid conceiving from signing the ICD, while
participating in the study, during dose interruptions, and for at least 106 days
following CC-90010 discontinuation, even if he has undergone a successful vasectomy.
Additionally, subjects must not donate sperm during this same time period.
Principal Exclusion Criteria
1. Subject has received anti-cancer therapy (either approved or investigational) within
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
Gustave Roussy - Cancer Campus
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.)
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale
Istituto Clinico Humanitas
Aichi Cancer Center Hospital
National Cancer Center Hospital East
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Hospital Val d'Hebron
Hospital Universitario Fundacion Jimenez Diaz
Hospital 12 de Octubre
Study Director: Zariana Nikolova, MD, PhD Celgene